An observational study in COVID-19, Testosterone Deficiency and Infertility, Male, sponsored by IRCCS San Raffaele. Recruiting at 1 site in Italy. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-20.
Sponsored by IRCCS San Raffaele · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in COVID-19 by IRCCS San Raffaele — 1 open to participants now, 3 under way, none of them phase 3. COVID-19 · IRCCS San Raffaele.
Among the 12 studies in COVID-19 by IRCCS San Raffaele, this one has the largest planned enrollment of the 10 observational ones that give a count, is one of 8 that started in 2020, is one of 10 observational ones, and was the 9th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →1 of the 12 studies in COVID-19 by IRCCS San Raffaele is open now, in 1 country.
By country, each count listing its studies:
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2020; this study’s year is marked. 8 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 268 across 3,209 observational studies indexed under COVID-19.
Median enrollment 32 across the 2 interventional studies, 400 across the 10 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
IRCCS San Raffaele is the lead sponsor of 458 studies on the registry; 237 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in COVID-19 by IRCCS San Raffaele, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The hormonal environment (steroid, primarily) could have a very relevant pathophysiological role in association with SARS-CoV-2. That is, testosterone could play a relevant role in leaving male subjects more exposed to infection and more prone to developing severe complications following COVID-19 infection.
Preliminary data suggests that male individuals are more susceptible to COVID-19 infection, at least in Western countries, and that their mortality rate is higher than female individuals. This would seem to suggest that the hormonal environment (steroid, primarily) could have a very relevant pathophysiological role in association with SARS-CoV-2. That is, testosterone could play a relevant role in leaving male subjects more exposed to infection and more prone to developing severe complications following COVID-19 infection. Another option is that COVID-19 infection could cause a condition of acute hypogonadism, following which, the exhaustion of androgenic action could act as a co-trigger of a severe or even fatal course of the disease.
Male COVID-19 patients and male healthy individuals
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient Cohort:
Control Cohort:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Male patients with an age \> 18 affected by COVID-19 with biological samples positive for SARS-CoV-2 but with negative test
Diagnostic Test: Collection of biological data
Healthy donors with an age\> 18 accessing the IRCCS OSR Blood Donor Center
Diagnostic Test: Collection of biological data
Biological sample will be collected from the COVID19 patients and from healthy donors
Dosage of the androgenic hormonal environment in the blood of patients and healthy controls
Time frame: Baseline
create an international (European) registry for the management of sensitive data in epidemiological terms and pathology outcomes relating to males with confirmed COVID-19 infection and age-matched healthy controls
Time frame: Baseline
Plan to share: No
No publications or documents are linked to this record.
Started May 2020 (actual). Primary completion is estimated for May 2025, 59 months after the start.
Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 59 months is above that.
Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.